News from mallinckrodt plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 24, 2019, 06:55 ET Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)

Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in...


Jun 13, 2019, 06:45 ET All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)

Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical company, is reporting that all primary and secondary outcome measures were met in...


Jun 05, 2019, 12:46 ET Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation Activities

Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical company, today reported the company has reached an agreement in principle with the ...


May 29, 2019, 06:55 ET Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)

Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter...


May 28, 2019, 06:45 ET Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced updated plans for its spin-off of a new company consisting of...


May 21, 2019, 16:30 ET Mallinckrodt Announces Election of Carlos V. Paya, M.D., Ph.D. to its Board of Directors

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today the election of Carlos V. Paya, M.D., Ph.D. to the...


May 21, 2019, 06:59 ET Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® Gel

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed its subsidiary, Mallinckrodt ARD LLC (Mallinckrodt), has filed suit ...


May 14, 2019, 06:55 ET Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that the company has achieved target enrollment of...


May 07, 2019, 06:00 ET Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data Generation

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the three months ended March 29, 2019....


May 06, 2019, 06:45 ET Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax® (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced preliminary results of a planned interim analysis...


May 02, 2019, 06:55 ET Mallinckrodt to Present Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis at Annual European Congress of Rheumatology (EULAR 2019)

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, has completed the controlled, double-blind, randomized second phase...


Apr 24, 2019, 16:34 ET Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis.

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today celebrated the completion of its expanded operations and...


Apr 23, 2019, 06:45 ET Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed it has completed enrollment in the company's Phase 4 ...


Apr 15, 2019, 06:45 ET Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, is reporting data from a retrospective analysis of data from the...


Apr 12, 2019, 06:45 ET Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has...


Apr 10, 2019, 17:00 ET Mallinckrodt's INOmax™ (Nitric Oxide) Gas, for Inhalation, Approved in Australia for Pulmonary Hypertension in Adults in Conjunction with Cardiovascular Surgery

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that INOmax™ (nitric oxide) gas, for inhalation has...


Apr 09, 2019, 06:45 ET Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced data from a retrospective chart review that analyzed ...


Apr 05, 2019, 14:02 ET Mallinckrodt anuncia estudo que demonstra eficácia da imunomodulação com FEC, como acessório à terapia padrão local, no tratamento de pacientes de transplante de pulmão com síndrome de bronquiolite obliterante (SBO)

A Mallinckrodt plc (NYSE: MNK), grande empresa farmacêutica de especialidades, anuncia a apresentação de um estudo retrospectivo, que demonstra a...


Mar 28, 2019, 17:45 ET Mallinckrodt Achieves Top Score in 2019 Corporate Equality Index for Third Year in a Row, Recognized as a Best Place to Work for LGBTQ Equality

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that the company received a perfect score of 100...


Mar 27, 2019, 06:55 ET Mallinckrodt plc To Report Earnings Results For First Quarter 2019

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today that it will report first quarter 2019 earnings...


Mar 18, 2019, 06:45 ET Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer (CFO)

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that, following an extensive search, Bryan Reasons...


Mar 04, 2019, 06:55 ET Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced data from a retrospective cohort analysis that...


Feb 26, 2019, 06:05 ET Mallinckrodt plc Reports Strong Fourth Quarter and Total Company 2018 Results, Announces 2019 Guidance and Strategic Priorities

Fourth quarter net sales of $834.9 million, a 5.4% increase; 2018 net sales of $3.2 billion comparable to prior year Fourth quarter operating cash...


Feb 25, 2019, 12:22 ET Mallinckrodt anuncia acordo de colaboração para pesquisa sobre fotoferese extracorpórea (FEC) com a Transimmune AG

A Mallinckrodt plc (NYSE:MNK), importante empresa farmacêutica especializada e global, anunciou hoje que celebrou um acordo de colaboração...